Rospotrebnadzor announced the production of antibodies in those vaccinated with EpiVacCorona

Almost 96% of those vaccinated with EpiVacCorona developed a sufficient amount of antibodies to the CORONAVIRUS. This was announced by the deputy DIRECTOR for scientific work of the Central Research Institute of Epidemiology of Rospotrebnadzor Alexander Gorelov on the air of the RUSSIA 1 TV channel.

“95.8% of people developed enough antibodies, and 4.2% of those vaccinated had null antibodies,” Gorelov said.

Popova turned out to be one of the developers of the EpiVacCorona vaccine Society

The EpiVacCorona drug from the Novosibirsk Research Center Vector of Rospotrebnadzor was registered in Russia in October 2020. This is the second Russian vaccine against covid-19 . Clinical trials of the drug began in December. The vaccine entered civilian circulation on January 1. it was created on the basis of artificially synthesized fragments of the S-protein of the SARS-CoV-2 virus. According to Rospotrebnadzor, the results of two phases of clinical trials showed that the effectiveness of the vaccine was 100%.

June 8, 11:15 Moscow time Coronavirus Russia Moscow World +8883 (per day) 4.7 million Recovered 0 +9977 (per day) 5.1 million Infected 0 +379 (per day) 124.5 thousand Died +2018 ( per day) 1.1 million Recovered 0 +3817 (per day) 1.2 million Infected 0 +62 (per day) 20.6 thousand Died +596267 (per day) 111.6 million Recovered 0 +322913 (per day) ) 173.6 million Infected 0 +7996 (per day) 3.7 million Died Source: JHU,
federal and regional
virus control headquarters Source: JHU, federal and regional virus control headquarters Read more